NCT03847987View on ClinicalTrials.gov

A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

April 22, 2019

Study Completion Date

April 22, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

RO7017773 Phase I Capsule

Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.

DRUG

RO7017773 Phase II Tablet Unflavored

Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.

DRUG

RO7017773 Phase II Tablet Sweetened/Flavored

Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.

Trial Locations (1)

84124

PRA Health Sciences, Salt Lake City

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03847987 - A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants | Biotech Hunter | Biotech Hunter